Cervical cancer

Paul A Cohen, Anjua Jhingran, Ana Oaknin, Lynette Denny

Research output: Contribution to journalReview article

Abstract

Each year, more than half a million women are diagnosed with cervical cancer and the disease results in over 300 000 deaths worldwide. High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in most cases. The disease is largely preventable. Approximately 90% of cervical cancers occur in low-income and middle-income countries that lack organised screening and HPV vaccination programmes. In high-income countries, cervical cancer incidence and mortality have more than halved over the past 30 years since the introduction of formal screening programmes. Treatment depends on disease extent at diagnosis and locally available resources, and might involve radical hysterectomy or chemoradiation, or a combination of both. Conservative, fertility-preserving surgical procedures have become standard of care for women with low-risk, early-stage disease. Advances in radiotherapy technology, such as intensity-modulated radiotherapy, have resulted in less treatment-related toxicity for women with locally-advanced disease. For women with metastatic or recurrent disease, the overall prognosis remains poor; nevertheless, the incorporation of the anti-VEGF agent bevacizumab has been able to extend overall survival beyond 12 months. Preliminary results of novel immunotherapeutic approaches, similarly to other solid tumours, have shown promising results so far.

LanguageEnglish
Pages169-182
Number of pages14
JournalThe Lancet
Volume393
Issue number10167
DOIs
Publication statusPublished - 12 Jan 2019

Fingerprint

Uterine Cervical Neoplasms
Papillomaviridae
Intensity-Modulated Radiotherapy
Virus Diseases
Standard of Care
Hysterectomy
Vascular Endothelial Growth Factor A
Fertility
Vaccination
Radiotherapy
Technology
Survival
Mortality
Incidence
Therapeutics
Neoplasms

Cite this

Cohen, Paul A ; Jhingran, Anjua ; Oaknin, Ana ; Denny, Lynette. / Cervical cancer. In: The Lancet. 2019 ; Vol. 393, No. 10167. pp. 169-182.
@article{8b539d9ebe5546b2b12d5fcc8a1443a3,
title = "Cervical cancer",
abstract = "Each year, more than half a million women are diagnosed with cervical cancer and the disease results in over 300 000 deaths worldwide. High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in most cases. The disease is largely preventable. Approximately 90{\%} of cervical cancers occur in low-income and middle-income countries that lack organised screening and HPV vaccination programmes. In high-income countries, cervical cancer incidence and mortality have more than halved over the past 30 years since the introduction of formal screening programmes. Treatment depends on disease extent at diagnosis and locally available resources, and might involve radical hysterectomy or chemoradiation, or a combination of both. Conservative, fertility-preserving surgical procedures have become standard of care for women with low-risk, early-stage disease. Advances in radiotherapy technology, such as intensity-modulated radiotherapy, have resulted in less treatment-related toxicity for women with locally-advanced disease. For women with metastatic or recurrent disease, the overall prognosis remains poor; nevertheless, the incorporation of the anti-VEGF agent bevacizumab has been able to extend overall survival beyond 12 months. Preliminary results of novel immunotherapeutic approaches, similarly to other solid tumours, have shown promising results so far.",
keywords = "SQUAMOUS-CELL CARCINOMA, PELVIC RADIATION-THERAPY, HUMAN-PAPILLOMAVIRUS VACCINATION, RADICAL-TRACHELECTOMY, LYMPH-NODE, CONCURRENT CISPLATIN, PLUS CISPLATIN, UTERINE CERVIX, OPEN-LABEL, PHASE-III",
author = "Cohen, {Paul A} and Anjua Jhingran and Ana Oaknin and Lynette Denny",
year = "2019",
month = "1",
day = "12",
doi = "10.1016/S0140-6736",
language = "English",
volume = "393",
pages = "169--182",
journal = "Lancet",
issn = "0140-6736",
publisher = "Academic Press",
number = "10167",

}

Cohen, PA, Jhingran, A, Oaknin, A & Denny, L 2019, 'Cervical cancer', The Lancet, vol. 393, no. 10167, pp. 169-182. https://doi.org/10.1016/S0140-6736, https://doi.org/10.1016/S0140-6736(18)32470-X

Cervical cancer. / Cohen, Paul A; Jhingran, Anjua; Oaknin, Ana; Denny, Lynette.

In: The Lancet, Vol. 393, No. 10167, 12.01.2019, p. 169-182.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Cervical cancer

AU - Cohen, Paul A

AU - Jhingran, Anjua

AU - Oaknin, Ana

AU - Denny, Lynette

PY - 2019/1/12

Y1 - 2019/1/12

N2 - Each year, more than half a million women are diagnosed with cervical cancer and the disease results in over 300 000 deaths worldwide. High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in most cases. The disease is largely preventable. Approximately 90% of cervical cancers occur in low-income and middle-income countries that lack organised screening and HPV vaccination programmes. In high-income countries, cervical cancer incidence and mortality have more than halved over the past 30 years since the introduction of formal screening programmes. Treatment depends on disease extent at diagnosis and locally available resources, and might involve radical hysterectomy or chemoradiation, or a combination of both. Conservative, fertility-preserving surgical procedures have become standard of care for women with low-risk, early-stage disease. Advances in radiotherapy technology, such as intensity-modulated radiotherapy, have resulted in less treatment-related toxicity for women with locally-advanced disease. For women with metastatic or recurrent disease, the overall prognosis remains poor; nevertheless, the incorporation of the anti-VEGF agent bevacizumab has been able to extend overall survival beyond 12 months. Preliminary results of novel immunotherapeutic approaches, similarly to other solid tumours, have shown promising results so far.

AB - Each year, more than half a million women are diagnosed with cervical cancer and the disease results in over 300 000 deaths worldwide. High-risk subtypes of the human papilloma virus (HPV) are the cause of the disease in most cases. The disease is largely preventable. Approximately 90% of cervical cancers occur in low-income and middle-income countries that lack organised screening and HPV vaccination programmes. In high-income countries, cervical cancer incidence and mortality have more than halved over the past 30 years since the introduction of formal screening programmes. Treatment depends on disease extent at diagnosis and locally available resources, and might involve radical hysterectomy or chemoradiation, or a combination of both. Conservative, fertility-preserving surgical procedures have become standard of care for women with low-risk, early-stage disease. Advances in radiotherapy technology, such as intensity-modulated radiotherapy, have resulted in less treatment-related toxicity for women with locally-advanced disease. For women with metastatic or recurrent disease, the overall prognosis remains poor; nevertheless, the incorporation of the anti-VEGF agent bevacizumab has been able to extend overall survival beyond 12 months. Preliminary results of novel immunotherapeutic approaches, similarly to other solid tumours, have shown promising results so far.

KW - SQUAMOUS-CELL CARCINOMA

KW - PELVIC RADIATION-THERAPY

KW - HUMAN-PAPILLOMAVIRUS VACCINATION

KW - RADICAL-TRACHELECTOMY

KW - LYMPH-NODE

KW - CONCURRENT CISPLATIN

KW - PLUS CISPLATIN

KW - UTERINE CERVIX

KW - OPEN-LABEL

KW - PHASE-III

U2 - 10.1016/S0140-6736

DO - 10.1016/S0140-6736

M3 - Review article

VL - 393

SP - 169

EP - 182

JO - Lancet

T2 - Lancet

JF - Lancet

SN - 0140-6736

IS - 10167

ER -